Skip to Main Content

Paper Details

Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Cancer
13
2021
ATM, BRCA1, BRCA1/2, BRCA1/2 mutations, CDK12, CDK12 mutations, DDRm, DNA, DNA damage repair mutations, PSA50, Patient, abiraterone, cabazitaxel, carboplatin, docetaxel, enzalutamide, mCRPC, men, metastatic castration-resistant prostate cancer, patients, prostate-specific antigen
Author NameAffiliation
Jonathan ChouUniversity of California San Francisco
Melissa A ReimersWashington University
Rahul AggarwalUniversity of California San Francisco
Alexander W Wyatt
Alexander W WyattUniversity of British Columbia
Eric J SmallUniversity of California San Francisco
Kim N Chi
Kim N Chi
Felix Y FengUniversity of California San Francisco
  • 1 - 9

Datasets

Release 1.2